SUMMARY
The authors propose a novel noninvasive therapeutic approach for degenerative calcified bioprosthetic heart valves based on pulsed cavitational ultrasound (PCU) to improve the valvular function by remotely softening calcified stiff cusps. This study aims to demonstrate both in vivo, using an ovine model with implanted human calcified bioprosthesis, and in vitro that PCU can significantly improve the bioprosthesis function. A 50% decrease of the transvalvular gradient was found, demonstrating a strong improvement of the valve opening function. This new noninvasive approach has the potential to improve the outcomes of patients with severe bioprosthesis stenosis. 15 years, mainly due to intravalvular calcifications (2) . The need for a redo surgery due to the incidence of structural valve deterioration is expected to increase (3) . Nevertheless, redo valve surgery is associated with significant morbidity and mortality (4) .
Transcatheter valve-in-valve
implantation has emerged as a promising, less invasive alternative to redo surgery; however, it still comes with its own various set of complications (5) .
In parallel, for about 30 years, other therapeutic strategies (6,7) have been investigated to treat calcified valves (native or bioprosthetic). One promising approach was ultrasound-based (8) , but it remained Histotripsy is a noninvasive, cavitation-based therapy (mechanical effect) based on very short, highpressure ultrasound pulses focused in tissues to generate a dense, energetic, lesion-producing bubble cloud. Although histotripsy can be used to produce sharp lesions in soft tissues (9, 10) , recent studies have suggested that cavitation activity can also soften biological tissues (11) .
The objective of our study was to evaluate the ef- .
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Noninvasive Ultrasound Therapy of Calcified Bioprosthesis 2500A, RITEC, Warwick, Rhode Island). We produced PCU using 10-cycle pulses, each 8 ms long, delivered at a pulse repetition frequency of 100 Hz. We estimated the pressure peak amplitudes at the focal spot to be 70 and À19 MPa, respectively, for the positive and negative peak pressure.
ULTRASOUND CAVITATIONAL TREATMENT GUIDANCE AND MONITORING. Three-dimensional echocardiography was used to guide and monitor the treatment. The pump operated during 2 h at a 4 l/min flow rate (70 cycles/min, ejection volume: 57 ml) to control the variation of the gradient before PCU, after which sequences of PCU were applied. All post-PCU transvalvular gradients were reassessed 1 month after the procedure (each valve was fixed in glutaraldehyde between these evaluations). Elastography was performed before and after the procedure on each valve.
Finally, the bioprostheses were sent to the department of pathology for histopathological analysis.
IN VIVO PROCEDURE: SHEEP MODEL. The in vivo procedure is shown in Figure 2C . The animal
The imaging probe was fixed through a hole in the center of the pulsed cavitational ultrasound therapy transducer.
Noninvasive Ultrasound Therapy of Calcified Bioprosthesis Lifesciences) were monitored. The CPB was stopped and removed to restore independent cardiac activity.
Sternotomy was maintained and the thorax was filled with degassed saline water. A complete echocardiography was performed, especially to evaluate the calcified bioprosthesis (12) (13) (14) . A total of 14 explanted bioprostheses were used for this procedure.
We then applied the sequences of PCU. An echocardiographic evaluation was performed between each 10-min sequence, concurrent with the catheter's evaluation (pressure and cardiac flow).
At the end of the procedure, the animal was sacrificed (Dolethal intravenous injection, 1 ml/kg) and an anatomic macroscopic evaluation of the cardiac structure was performed. Elastography examination of the bioprosthesis was performed before and after each procedure. The bioprosthesis was then explanted and sent after elastography to the department of pathology for histopathological analysis.
MICROSCOPIC ANALYSIS. Histological exploration.
Immediately after the procedure (in vitro and in vivo), the bioprosthesis was dissected, fixed in formalin, and embedded in individual paraffin blocks.
Regions of interest, such as macroscopic calcification on leaflet, were labelled with tattoo ink. Serial sections were stained with hematoxylin and eosin for histopathological analysis.
In addition, we also analyzed 5 calcified bioprostheses directly after their explantation from humans, without any PCU procedure. The objective was to perform a histopathological comparison between bioprostheses with or without PCU.
Micro-compu ted t omo graph y imagin g. files, using standard back-projection techniques. 
Noninvasive Ultrasound Therapy of Calcified Bioprosthesis Mean transvalvular gradient measured before and after pulsed cavitational ultrasound. During PCU a "cavitation bubble cloud" is visible as a hyperechogenic zone (red arrow). After PCU, the improvement of the bioprosthesis opening is confirmed thanks to the echocardiography (green arrow). The images are realized during diastasis (closed aortic valve). See Supplemental Video 1. Ao ¼ aorta; other abbreviations as in Figure 2 .
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Noninvasive Ultrasound Therapy of Calcified Bioprosthesis We observed an important decrease of the transvalvular gradient after PCU (Table 1) , which was on average reduced by 50%. The results of elastography, echocardiography, and of pressure/flow cardiac catheters after the PCU procedures are synthesized in No mitral valve regurgitation was observed at the end of the procedures.
We observed isolated ventricular extrasystoles in 2 animals, without any repercussion in hemodynamic parameters. As long as the focal spot of the therapy device remained on the bioprosthesis, no arrhythmia was visible.
After the threshold was reached and all parameters were re-evaluated, the animal was sacrificed and the heart was explanted. Macroscopic analysis showed that all cardiac structures were intact ( Villemain et al.
Noninvasive Ultrasound Therapy of Calcified Bioprosthesis Macroscopic analysis showed that all cardiac structures were intact. The whole hearts appeared intact from the outside, with no visible damage on the epicardial surfaces (except in 2 animals in which a 7-mm diameter superficial hematoma [epicardium] was visible). After dissection, no damage was observed inside of the heart.
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histological lesions due to PCU noted inside the calcification (vacuole) seem to preserve the overall architecture of the valve leaflet.
Concerning cardiac application of PCU, in 2009, Xu et al. (21) showed that the size of myocardium debris obtained after histotripsy was inferior to the size of a red blood cell for >99% of the debris. As of now, no studies have been conducted specifically on valvular calcifications and PCU.
STUDY LIMITATIONS. In vivo follow-up. We observed stability of the transvalvular gradient in vitro 1 month after the procedure. However, this was not confirmed for the in vivo procedure, because we sacrificed the animals directly after the procedure. It is, therefore, difficult to evaluate the persistence of the therapeutic effect.
S h e a r w a v e e l a s t o g r a p h y e v a l u a t i o n . Shear wave elastography has never been used for the stiffness evaluation of valve leaflets; therefore, this application needs to be validated in further studies. After pulsed cavitational focused ultrasound, the superficial structures remain intact (A). An aspect of calcification fragmentation is visible (B).
Some vacuoles are also found inside of the calcifications (C). 
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